<DOC>
	<DOCNO>NCT00003640</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop tumor cell divide stop grow die . Combination chemotherapy combine transurethral resection may kill tumor cell . PURPOSE : Phase II trial study effectiveness transurethral resection plus combination chemotherapy treat patient stage II stage III bladder cancer .</brief_summary>
	<brief_title>Transurethral Resection Combination Chemotherapy Treating Patients With Stage II Stage III Bladder Cancer</brief_title>
	<detailed_description>OBJECTIVES : I . Determine percentage patient transitional cell carcinoma bladder disease free minimal disease 3 month thorough transurethral resection ( TURB ) escalate dose methotrexate/vinblastine/doxorubicin/cisplatin ( M-VAC ) chemotherapy . II . Evaluate combination thorough TURB escalate dose M-VAC follow radiotherapy respect bladder preservation patient respond neoadjuvant chemotherapy . III . Evaluate proportion patient remain disease free require cystectomy 1 year . IV . Evaluate feasibility morbidity treatment schedule multiple institution apply urologist possibly vary endoscopic ability . OUTLINE : This multicenter study . Patients undergo local transurethral resection . Patients receive methotrexate IV day 1 , follow vinblastine IV , doxorubicin IV , cisplatin IV day 2 . Filgrastim ( G-CSF ) administer day 4-10 . Chemotherapy repeat every 14 day 3 course . After end chemotherapy , patient undergo another local transurethral resection order define response treatment . Patients minimal disease treat radiotherapy . Patients still disease undergo cystectomy . Patients follow every 3 month first 2 year , every 6 month death . PROJECTED ACCRUAL : A total 29-73 patient accrue study .</detailed_description>
	<mesh_term>Urinary Bladder Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Transitional Cell</mesh_term>
	<mesh_term>Methotrexate</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<mesh_term>Liposomal doxorubicin</mesh_term>
	<mesh_term>Vinblastine</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Transitional cell carcinoma bladder biopsy proven muscle invasion suitable resection leave residual visible palpable tumor mass Unifocal No great 5 cm Stages II III ( T2T3a , N0NX , M0 ) No prior treatment bladder cancer endoscopic resection , intravesical chemotherapy , intravesical immunotherapy PATIENT CHARACTERISTICS : Age : Not specify Performance status : WHO 01 Life expectancy : Not specify Hematopoietic : WBC least 3,500/mm3 Platelet count least 120,000/mm3 Hepatic : Bilirubin normal SGOT/SGPT normal Renal : GFR least 50 mL/min Cardiovascular : Normal cardiac function ( i.e. , New York Heart Association class IIIV ) Other : Normal auditory function No second primary malignant tumor except basal cell carcinoma skin Fit cisplatin contain combination chemotherapy , radical radiotherapy , cystectomy No active infection Not pregnant nursing No concurrent illness significantly affect clinical assessment PRIOR CONCURRENT THERAPY : Biologic therapy : See Disease Characteristics Chemotherapy : See Disease Characteristics No prior systemic chemotherapy Endocrine therapy : Not specify Radiotherapy : No prior radiotherapy bladder Surgery : See Disease Characteristics No prior partial cystectomy Prior transurethral resection bladder allow</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2012</verification_date>
	<keyword>stage II bladder cancer</keyword>
	<keyword>stage III bladder cancer</keyword>
	<keyword>transitional cell carcinoma bladder</keyword>
</DOC>